CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis.
Saved in:
| Title: | CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis. |
|---|---|
| Authors: | Thacker SG; Laboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America., McWilliams IL; Laboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America., Bonnet B; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland., Halie L; Laboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America., Beaucage S; Laboratory of Biological Chemistry; Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America., Rachuri S; Laboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America., Dey R; Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America., Duncan R; Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America., Modabber F; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland., Robinson S; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland., Bilbe G; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland., Arana B; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland., Verthelyi D; Laboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America. |
| Source: | PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2020 Feb 28; Vol. 14 (2), pp. e0008050. Date of Electronic Publication: 2020 Feb 28 (Print Publication: 2020). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488 Publication Model: eCollection Cited Medium: Internet ISSN: 1935-2735 (Electronic) Linking ISSN: 19352727 NLM ISO Abbreviation: PLoS Negl Trop Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1935-2735 |
|---|---|
| DOI: | 10.1371/journal.pntd.0008050 |
